Prometheus Biosciences, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)

This study tested a new drug called tulisokibart (PRA023) in 55 people with moderate-to-severe Crohn's disease who had not responded well to other treatments. The main goals were to check safety and see if the drug could improve gut healing and reduce symptoms. After 12 weeks, so…